OR WAIT 15 SECS
Nexavar gains new indication approval for liver cancer
Nexavar (sorafenib) tablets, originally approved to treat advanced kidney cancer, have just been approved for a new indication. The kinase inhibitor can now be used to treat liver cancer as well. The oral anticancer drug, a product of Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, was approved on a priority review basis. According to Bayer, sorafenib is the first approved systemic therapy for liver cancer and the only one shown to significantly improve survival.
Click here to see more articles from Drug Topics Daily News.
To go to the Drug Topics homepage, click here.